Investigating acquired resistance to novel Pol I transcription inhibitors for the treatment of haematologic malignancies
Identifying novel cancer cell susceptibilities
M606, a novel small molecule inhibitor of MYCN oncoprotein
A novel molecule targeting protein translation, rapidly and selectively induces cell death in Mixed Lineage Leukaemia
ßIII-Tubulin supports cell growth and proliferation of glucose-starved Non-small Cell Lung Cancer cells by modulating multiple stress response signalling pathways.
Mitochondrial and mTOR pathway inhibition synergise to block pancreatic adenocarcinoma development
BET-bromodomain inhibition induces Myc-independent apoptosis via epigenetic regulation of BCL-2 family proteins in aggressive Myc-driven lymphoma.
Mechanistic insights into HDAC-inhibitors: Linking the Type-I Interferon Signaling Pathway with Differentiation Therapy in t(8;21) AML
Disabled negative feedback regulation by SPROUTY2 sustains EGFR, FGFR and c-MET mediated resistance to BRAF inhibitor treatment in melanoma
Protein-protein docking for the discovery of novel therapeutics that target the interaction between PTP1B and EGFR
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
Stathmin regulation of microRNA/mRNA expression in neuroblastoma cells
Incorporating Personalized Medicine in Early Drug Development Programs
- Previous
- ....